BQ Prime's special research section collates quality and in-depth equity and economy research reports from across India's top brokerages, asset managers and research agencies. These reports offer BQ Prime's subscribers an opportunity to expand their understanding of companies, sectors and the economy.
Dolat Capital Report
We like Natco Pharma Ltd.'s focus on niche drug filings, and expect strong cashflows backed by low competitive launches like gRevlimid.
We believe Natco's base business which was mainly impacted due to price erosion in its key products in the U.S. and pricing pressure in domestic oncology segment would see improvement gradually with focus on new launches.
We expect return ratios to improve and believe Natco to explore merger and acquisition opportunities in India on back of strong cashflows.
Click on the attachment to read the full report:
DISCLAIMER
This report is authored by an external party. BQ Prime does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BQ Prime.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.
Essential Business Intelligence, Continuous LIVE TV, Sharp Market Insights, Practical Personal Finance Advice and Latest Stories — On NDTV Profit.
